| Literature DB >> 34285130 |
Yangtao Wu1, Xiaofen Huang2,1, Lunzhi Yuan1, Shaojuan Wang1, Yali Zhang1, Hualong Xiong2,1, Rirong Chen3,4, Jian Ma2,1, Ruoyao Qi2,1, Meifeng Nie1, Jingjing Xu1, Zhigang Zhang1,1, Liqiang Chen3,4, Min Wei2,1, Ming Zhou2,1, Minping Cai3,4, Yang Shi1, Liang Zhang1, Huan Yu3,4, Junping Hong1, Zikang Wang1, Yunda Hong1, Mingxi Yue1, Zonglin Li1, Dabing Chen1, Qingbing Zheng2,1, Shaowei Li1, Yixin Chen2,1, Tong Cheng1, Jun Zhang5, Tianying Zhang6,1, Huachen Zhu7,3,4, Qinjian Zhao6,1, Quan Yuan5, Yi Guan8,4, Ningshao Xia6,1,2.
Abstract
Multiple safe and effective vaccines that elicit immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are necessary to respond to the ongoing coronavirus disease 2019 (COVID-19) pandemic. Here, we developed a protein subunit vaccine comprised of spike ectodomain protein (StriFK) plus a nitrogen bisphosphonate-modified zinc-aluminum hybrid adjuvant (FH002C). StriFK-FH002C generated substantially higher neutralizing antibody titers in mice, hamsters, and cynomolgus monkeys than those observed in plasma isolated from COVID-19 convalescent individuals. StriFK-FH002C also induced both Th1- and Th2-polarized helper T cell responses in mice. In hamsters, StriFK-FH002C immunization protected animals against SARS-CoV-2 challenge, as shown by absence of virus-induced weight loss, fewer symptoms of disease, and reduced lung pathology. Vaccination of hamsters with StriFK-FH002C also reduced within-cage virus transmission to unvaccinated, cohoused hamsters. In summary, StriFK-FH002C represents an effective, protein subunit-based SARS-CoV-2 vaccine candidate.Entities:
Year: 2021 PMID： 34285130 DOI： 10.1126/scitranslmed.abg1143
Source DB: PubMed Journal: Sci Transl Med ISSN： 1946-6234 Impact factor: 17.956